Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation

Abstract

A method for inhibiting the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process, said method comprising administering to said cell an anti-inflammatory polysaccharide composition comprising fucans and galactans to a cell, wherein the ratio of fucans to galactans in said composition enables a reduction in the cytotoxicity of said galactans and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of ranging from about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight ranging from about 0.1 kDa and 100 kDa.

1 . A method for inhibiting the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process, said method comprising administering to said cell an anti-inflammatory polysaccharide composition comprising fucans and galactans to a cell, wherein the ratio of fucans to galactans in said composition enables a reduction in the cytotoxicity of said galactans. 
     
     
         2 . The method of  claim 1 , wherein the release of IL-8, PGE2 and VEGF is from epithelial cells. 
     
     
         3 . The method of  claim 1 , wherein the fucans increase the inhibition of inflammation. 
     
     
         4 . The method of  claim 1 , wherein (a) the galactans comprise galactans obtained from red algae; and/or (b) the fucans comprise fucans obtained from brown algae. 
     
     
         5 . The method of  claim 4 , wherein (a) the red algae comprises  Asparagopsis armata ; and/or (b) the brown algae comprises  Ascophyllum nodosum.    
     
     
         6 . The method of  claim 1 , wherein the galactans have an average molecular weight higher than about 100 kDa. 
     
     
         7 . The method of  claim 1 , wherein the galactans have an average molecular weight of about 350 kDa. 
     
     
         8 . The method of  claim 1 , wherein (a) the galactans have a galactose content of about 30% to about 40% of dry weight of the galactans; (b) the galactans have an uronic acid content of about 1% to about 5% of dry weight of the galactans; (c) wherein the galactans have a sulfate content of about 20% to about 35% of dry weight of the galactans; (d) the fucans have an average molecular weight ranging from about 0.1 kDa to about 100 kDa; (e) the fucans have a fucose content of about 20-35% of dry weight of the fucans; (f) the fucans have an uronic acid content of about 10 to about 29% of dry weight of the fucans; (g) the fucans have a sulfate content of about 15 to about 25% of dry weight of the fucans; (h) the fucans anf the galactans in said composition are present in a ratio of from about 2.5 fucans/1 galactans (w/w) to about 40 fucans/1 galactans (w/w); (i) the galactans comprise native galactans; (j) the fucans comprise native fucans; (k) the fucans comprise depolymerized fucans; (l) the fucans comprise demineralized fucans; and/or (m) the galactans comprise demineralized galactans. 
     
     
         9 . The method of  claim 8 , wherein (a) the galactans have a galactose content of about 37% of dry weight of the galactans; (b) the galactans have an uronic acid content of about 3% of dry weight of the galactans; (c) the galactans have a sulfate content of about 27% of dry weight of the galactans; (d) the fucans have an average molecular weight ranging from about 5 kDa to about 25 kDa; and/or (e) the fucans and the galactans are present in a ratio of about 10 fucans/1 galactans (w/w) in the composition. 
     
     
         10 . The method of  claim 1 , wherein said composition is administered topically. 
     
     
         11 . The method of  claim 10 , for (a) alleviating or improving skin disorders or conditions caused by UV exposure, chemical stress or aggression from pollutants, exfoliating agents or skin irritants; or (b) preventing skin disorders or conditions caused by UV exposure, chemical stress or aggression from pollutants, exfoliating agents or skin irritants. 
     
     
         12 . The method of  claim 1 , wherein the cell is within a subject. 
     
     
         13 . The method of  claim 12 , wherein the polysaccharide composition is topically administered to the subject. 
     
     
         14 . The method of  claim 13 , wherein the subject is a human affected by skin disorders or conditions caused by UV exposure, chemical stress, or aggression from pollutants, exfoliating agents or skin irritants. 
     
     
         15 . An anti-inflammatory composition comprising brown algae fucans and red algae galactans, wherein the ratio of brown algae fucans/red algae galactans in said composition is ranging from about 2.5/1 (w/w) to about 40/1 (w/w), said galactans having a molecular weight higher than about 100 kDa and said fucans having a molecular weight ranging from about 0.1 kDa and 100 kDa, wherein the ratio of fucans to galactans in said composition enables a reduction in the cytotoxicity of said galactans. 
     
     
         16 . The composition of  claim 15 , wherein (a) the galactans have an average molecular weight of about 350 kDa; (b) the galactans have a galactose content of about 30% to about 40% of dry weight of the galactans; (c) the galactans have an uronic acid content of about 1% to about 5% of dry weight of the galactans; (d) the galactans have a sulfate content of about 20% to about 35% of dry weight of the galactans; (e) the fucans have an average molecular weight ranging from about 5 kDa to about 25 kDa; (f) the fucans have a fucose content of about 20-35% of dry weight of the fucans; (g) the fucans have an uronic acid content of about 10 to about 29% of dry weight of the fucans; (h) the fucans have a sulfate content of about 15 to about 25% of dry weight of the fucans; (i) the ratio of brown algae fucans/red algae galactans is of 10/1; (j) the brown algae is  Ascophyllum nodosum ; (k) the red algae is  Asparagopsis armata ; (l) the galactans comprise native galactans; (m) the fucans comprise native fucans; (n) the fucans comprise depolymerized fucans; (o) the fucans comprise demineralized fucans; and/or (p) the galactans comprise demineralized galactans. 
     
     
         17 . The composition of  claim 16 , wherein (a) the galactans have a galactose content of about 37% of dry weight of the galactans; (b) the galactans have an uronic acid content of about 3% of dry weight of the galactans; and/or (c) the galactans have a sulfate content of about 27% of dry weight of the galactans. 
     
     
         18 . The composition of  claim 15 , wherein the galactans have a molecular weight of about 350 kDa, and the fucans have a molecular weight ranging from about 15 kDa and 25 kDa. 
     
     
         19 . The composition of  claim 15 , which is a topical composition. 
     
     
         20 . The composition of  claim 15 , which is a cosmetic composition.